1. The clinical and therapeutic profiles of prolactinomas associated with germline pathogenic variants in the aryl hydrocarbon receptor interacting protein (AIP) gene
- Author
-
Laurent Vroonen, Albert Beckers, Severine Camby, Thomas Cuny, Pablo Beckers, Marie-Lise Jaffrain-Rea, Muriel Cogne, Luciana Naves, Amandine Ferriere, Pauline Romanet, Atanaska Elenkova, Auli Karhu, Thierry Brue, Anne Barlier, Patrick Pétrossians, and Adrian F. Daly
- Subjects
prolactinoma ,genetic ,resistance ,dopamine agonist ,cabergoline ,AIP ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
IntroductionProlactinomas are the most frequent type of pituitary adenoma encountered in clinical practice. Dopamine agonists (DA) like cabergoline typically provide sign/ symptom control, normalize prolactin levels and decrease tumor size in most patients. DA-resistant prolactinomas are infrequent and can occur in association with some genetic causes like MEN1 and pathogenic germline variants in the AIP gene (AIPvar).MethodsWe compared the clinical, radiological, and therapeutic characteristics of AIPvar-related prolactinomas (n=13) with unselected hospital-treated prolactinomas (“unselected”, n=41) and genetically-negative, DA-resistant prolactinomas (DA-resistant, n=39).ResultsAIPvar-related prolactinomas occurred at a significantly younger age than the unselected or DA-resistant prolactinomas (p50%) occurred in 58.3% in the AIPvar group versus 4.2% in the DA-resistant group (p
- Published
- 2023
- Full Text
- View/download PDF